Information Provided By: 
Fly News Breaks for June 9, 2016
AGIO
Jun 9, 2016 | 06:53 EDT
JPMorgan analyst Anupam Rama says he remains remain cautious on Agios Pharmaceuticals shares ahead of this weekend's European Hematology Association update on the company's Pyruvate Kinase deficiency program. With the stock up 46% since May 19, Agios is pricing in a "very best case scenario" for the PKD program, Rama tells investors in a research note. He believes it may be too early to conclude a clear compelling benefit with AG-348. The analyst raised his price target for Agios to $50 from $39 and keeps a Neutral rating on the shares.
News For AGIO From the Last 2 Days
There are no results for your query AGIO
